Related Experiment Videos
Adriamycin therapy for advanced insulinoma.
The Journal of Clinical Endocrinology and Metabolism
|January 1, 1977
Summary
Advanced metastatic insulinoma patients resistant to chemotherapy showed positive responses to adriamycin-based treatments. These novel chemotherapy regimens offer potential for clinical remission in refractory insulinoma cases.
Area of Science:
- Oncology
- Endocrinology
Background:
- Insulinoma is a rare neuroendocrine tumor with metastatic potential.
- Advanced metastatic insulinoma often presents treatment challenges, with limited response to standard chemotherapy like streptozotocin.
Observation:
- Two patients with advanced metastatic insulinoma were treated after failing conventional chemotherapy.
- Patient 1 received adriamycin; Patient 2 received adriamycin plus 5-fluorouracil.
Findings:
- Both patients experienced significant reductions in insulin levels and/or measurable disease.
- Clinical remissions lasting 5 to 7 months were observed in both cases.
Implications:
- Adriamycin-based chemotherapy demonstrates potential efficacy in advanced insulinoma unresponsive to traditional treatments.
- These findings suggest adriamycin as a viable therapeutic option for refractory metastatic insulinoma.